📰 Multicenter Study News
Page 3 - Multicenter Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Multicenter Study. Real-time updates on events, politics, business and more.
February 19, 2023
The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT No New... | February 18, 2023
February 19, 2023
The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT (pNo New Safety Signals Were Seen with Vedolizumab Compared with Placebo in Patients Who Received Allo-HSCTData Were Presented as A La...
December 13, 2022
The following is a summary of "Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN" published in the December 2022 issue of Gastroenterology by Yerushalmy-Feler et al. Although there were no data for children, increasing the maintenance
December 12, 2022
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced two presentations of NKTR-255 at the 64th American Society of Hematology (ASH) Annual...
December 3, 2022
First results from LIGHTHOUSE trial presented at 23rd Annual Scientific Meeting in Urologic Oncology (SUO)
December 2, 2022
− First results from LIGHTHOUSE trial presented at 23rd Annual Scientific Meeting in Urologic Oncology (SUO) –MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today...
December 1, 2022
- First results from LIGHTHOUSE trial presented at 23rd Annual Scientific Meeting in Urologic Oncology (SUO) - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and
November 23, 2022
Diagnosing long COVID is something of an art for doctors who, without any formal criteria, say they know it when they see it.
November 3, 2022
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in...
November 3, 2022
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in...